Vivoryon Therapeutics N.V. Share Price
Stocks
VVY
NL00150002Q7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Amsterdam
16:55:00 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.8020 EUR | -2.67% |
|
-6.74% | -43.52% |
| 08-07 | Vivoryon Therapeutics N.V., H1 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 23.75M 26.52M 21.85M 19.8M 37M 2.52B 37.69M 261M 105M 1.32B 99.52M 97.41M 4.18B | P/E 2026 * |
-2.11x | P/E 2027 * | -2.17x |
|---|---|---|---|---|---|
| Enterprise Value | 28.07M 31.34M 25.82M 23.4M 43.73M 2.98B 44.55M 308M 124M 1.57B 118M 115M 4.94B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
95.15% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext AmsterdamEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| VVY | Real-time | |
Tradegate
| 05Y | Real-time | |
|
CBOE
| VVY | Real-time | |
|
Boerse Muenchen
| 05Y | Real-time | |
|
Deutsche Boerse AG
| 05Y | Delayed | |
|
CBOE
| 0R3M | Real-time | |
|
Börse Stuttgart
| 05Y | Delayed | |
|
Wiener Boerse
| VVYN | End-of-day quote |
Last Transcript: Vivoryon Therapeutics N.V.
| 1 day | -2.67% | ||
| 1 week | -6.74% | ||
| 1 month | -27.09% | ||
| 3 months | -32.89% | ||
| 6 months | -38.54% | ||
| Current year | -43.52% |
| 1 week | 0.77 |  | 0.89 |
| 1 month | 0.77 | | 1.1 |
| Current year | 0.77 | | 1.65 |
| 1 year | 0.77 | | 1.68 |
| 3 years | 0.41 | | 9.93 |
| 5 years | 0.41 | | 20.77 |
| 10 years | 0.41 | | 23.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 66 | 13/08/2023 |
Marcus Irsfeld
DFI | Director of Finance/CFO | - | 30/11/2025 |
Julia Neugebauer
COO | Chief Operating Officer | - | 30/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 31/12/2006 | |
Frank Weber
BRD | Director/Board Member | 66 | 14/09/2023 |
| Director/Board Member | 58 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/10/25 | Free | Chief Operating Officer | 20,000 | 0.0767% | ||
| 23/10/25 | Buy | Chief Executive Officer | 135,000 | 0.5179% | ||
| 23/10/25 | Free | 20,000 | 0.0767% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.67% | -6.74% | -51.22% | -89.76% | 26.52M | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +16.24% | +103.35% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.84% | +96.58% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +46.95% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | +0.04% | +6.11% | +37.70% | +166.51% | 39.44B | |
| Weighted average by Cap. | +0.18% | +5.44% | +47.99% | +176.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -10.4M -11.61M -9.57M -8.67M -16.2M -1.1B -16.51M -114M -45.8M -580M -43.58M -42.65M -1.83B | -10.4M -11.61M -9.57M -8.67M -16.2M -1.1B -16.51M -114M -45.8M -580M -43.58M -42.65M -1.83B |
| Net Debt | 4.32M 4.82M 3.97M 3.6M 6.73M 458M 6.86M 47.39M 19.02M 241M 18.1M 17.72M 760M | 13.03M 14.55M 11.99M 10.86M 20.3M 1.38B 20.68M 143M 57.38M 727M 54.6M 53.44M 2.29B |
Employees
13
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | €0.8020 | -2.67% | 90,778 |
| 29/10/26 | €0.8240 | -0.72% | 190,221 |
| 28/10/26 | €0.8300 | -1.66% | 28,174 |
| 27/10/26 | €0.8440 | +0.24% | 81,591 |
| 26/10/26 | €0.8420 | -2.09% | 32,418 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8020EUR
Average target price
6.850EUR
Spread / Average Target
+754.11%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VVY Stock
Select your edition
All financial news and data tailored to specific country editions
